Emerging resistance problems among respiratory tract pathogens

American Journal of Managed Care

Volumn 6, Issue 8 SUPPL., 2000, Pages

  Lister, Phillip D ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CIPROFLOXACIN; MACROLIDE; METICILLIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL PNEUMONIA; CONFERENCE PAPER; DRUG EFFICACY; HAEMOPHILUS INFLUENZAE; HUMAN; MORAXELLA CATARRHALIS; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, MICROBIAL; HUMANS; RESPIRATORY TRACT INFECTIONS;

EID: 0034032370     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (21)

1. Oh P, McIvor A. The pharmacoeconomics of respiratory tract infections. Clin Pulmonary Med 1996;3:323-328.
2. Bartlett JG, Breiman RF, Mandell LA, File TM Jr. Community-acquired pneumonia in adults: Guidelines for management. The Infectious Diseases Society of America. Clin Infect Dis 1998;26:811-838.
3. Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med 1995;333:1618-1624.
4. Doern GV. Trends in antimicrobial susceptibility of bacterial pathogens of the respiratory tract. Am J Med 1995;99(suppl 6B):3S-7S.
5. Doern GV, Brueggemann AB, Pierce G, Holley HP Jr, Rauch A. Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta-lactamase-positive strains resistant to amoxicillin-clavulanate: Results of a national multicenter surveillance study. Antimicrob Agents Chemother 1997;41:292-297.
6. Doern GV, Jones RN, Pfaller MA, Kugler K, and the SENTRY Participants Group. Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections: Antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). Antimicrob Agents Chemother 1999;43:385-389.
7. Bauernfeind A. Comparison of the antibacterial activities of the quinolones BAY 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother 1997;40:639-651.
8. Brueggemann AB, Kugler KC, Doern GV. In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob Agents Chemother 1997;41:1594-1597.
9. Spink WW, Ferris V. Quantitative action of penicillin inhibitor from penicillin-resistant strains of staphylococci. Science 1945;102:221.
10. Barber M. Methicillin-resistant staphylococci. J Clin Pathol 1961;14:385.
11. Jones RN, Barry AL, Gardiner RV, Packer RR. The prevalence of staphylococcal resistance to penicillinase-resistant penicillins. A retrospective and prospective trial of isolates from 40 medical centers. Diagn Microbiol Infect Dis 1989;12:385-394.
12. Sanders CC, Sanders WE Jr, Thomson KS. Fluoroquinolone resistance in staphylococci: New challenges. Eur J Clin Microbiol Infect Dis 1995;14(suppl 1):S6-S11.
13. Blumberg HM, Rimland D, Carroll DJ, Terry P, Wachsmuth IK. Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus. J Infect Dis 1991;163:1279-1285.
14. Pfaller MA, Jones RN, Doern GV, Sader HS, Kugler KC, Beach ML. Survey of blood stream infections attributable to gram-positive cocci: Frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Antimicrobial Surveillance Program. SENTRY Participants Group. Diagn Microbiol Infect Dis 1999;33:283-297.
15. Lister PD. Multiply-resistant pneumococcus: Therapeutic problems in the management of serious infections. Eur J Clin Microbiol Infect Dis 1995;14(suppl 1):S18-S25.
16. Doern GV, Pfaller MA, Kugler K, Freeman J, Jones RN. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY Antimicrobial Surveillance Program. Clin Infect Dis 1998;27:764-770.
17. Thornsberry C, Hickey ML, Diakun DR, et al. Sequential surveillance of antimicrobial resistance in the United States: Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis (1997-1998 vs. 1996-1997). Presented at: The 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, CA, September 24-27, 1998. [Abstract E-22].
18. Thornsberry C, Ogilvie P, Kahn J, Mauriz Y. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. Diagn Microbiol Infect Dis 1997;29:249-257.
19. Jacobs MR. Treatment and diagnosis of infections caused by drug-resistant Streptococcus pneumoniae. Clin Infect Dis 1992;15:119-127.
20. Doern GV, Brueggemann A, Holley HP Jr, Rauch AM. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: Results of a 30-center national surveillance study. Antimicrob Agents Chemother 1996;40:1208-1213.
21. Chen DK, McGeer A, de Azavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 1999;341:233-239.